The DOI matches its Crossref record.
Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease
Abstract
In a double-blind, placebo-controlled, parallel-group, randomized clinical trial, we studied the efficacy of long-term (1-year) oral treatment with acetyl-L-carnitine in 130 patients with a clinical diagnosis of Alzheimer's disease. We employed 14 outcome measures to assess functional and cognitive impairment. After 1 year, both the treated and placebo groups worsened, but the treated group showed a slower rate of deterioration in 13 of the 14 outcome measures, reaching statistical significance for the Blessed Dementia Scale, logical intelligence, ideomotor and buccofacial apraxia, and selective attention. Adjusting for initial scores with analysis of covariance, the treated group showed better scores on all outcome measures, reaching statistical significance for the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention. The analysis for patients with good treatment compliance showed a greater drug benefit than for the overall sample. Reported adverse events were relatively mild, and there was no significant difference between the treated and placebo groups either in incidence or severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Mitochondria as a Pharmacological Target
Szewczyk, A., & Wojtczak, L. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.1.101 · Cited by 538
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Jones, L. L., McDonald, D. A., & Borum, P. R. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.08.004 · Cited by 454
Metadata
- Authors
- Spagnoli, A., Lucca, U., Menasce, G., Bandera, L., Cizza, G., Forloni, G., Tettamanti, M., Frattura, L., Tiraboschi, P., Comelli, M., Senin, U., Longo, A., Petrini, A., Brambilla, G., Belloni, A., Negri, C., Cavazzuti, F., Salsi, A., Calogero, P., Parma, E., Stramba-Badiale, M., Vitali, S., Andreoni, G., Inzoli, M. R., Santus, G., Caregnato, R., Peruzza, M., Favaretto, M., Bozeglav, C., Alberoni, M., Leo, D. D., Serraiotto, L., Baiocchi, A., Scoccia, S., Culotta, P., & Ieracitano, D.
- Venue
- Neurology
- Published
- 1991-11
- Volume
- 41
- Issue
- 11
- Pages
- 1726-1726
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2005250105
- Cited by
- 232
- References
- 0
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease. https://app.cochat.ai/papers/10.1212/wnl.41.11.1726
- The paper
- Spagnoli, A., Lucca, U., Menasce, G., Bandera, L., Cizza, G., Forloni, G., Tettamanti, M., Frattura, L., Tiraboschi, P., Comelli, M., Senin, U., Longo, A., Petrini, A., Brambilla, G., Belloni, A., Negri, C., Cavazzuti, F., Salsi, A., Calogero, P., . . . Ieracitano, D. (1991). Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease. Neurology. https://doi.org/10.1212/wnl.41.11.1726
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.